The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Bueno, Héctor; Moura, Brenda; Lancellotti, Patrizio; Bauersachs, Johann

doi:10.1093/eurheartj/ehaa1061

Cited by 29 publications

(18 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, LVEF is only a crude estimate of LV function. 37 It is not sensitive to myocardial injury, or an ideal predictor for developing adverse LV remodeling. 38 , 39 A certain number of patients with normal LVEF developed adverse clinical outcomes while some patients with reduced LVEF at acute phase improved in the long‐term follow‐up.…”

Section: Discussionmentioning

confidence: 99%

Rationale and design of a multi‐center, prospective randomized controlled trial on the effects of sacubitril–valsartan versus enalapril on left ventricular remodeling in ST‐elevation myocardial infarction: The PERI‐STEMI study

Diao

Wang

Chen

et al. 2021

Clinical Cardiology

View full text Add to dashboard Cite

Background: Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril-valsartan has been recommended as one of the first-line therapies in heart failure with reduced ejection fraction. However, whether ARNI could benefit patients with ST-segment elevation myocardial infarction (STEMI) by improving left ventricular (LV) remodeling remains unknown. The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with STEMI than enalapril.Hypothesis: We hypothesize that sacubitril/valsartan is superior to enalapril in preventing adverse LV remodeling evaluated by cardiovascular magnetic resonance imaging at the 6-month follow-up.Methods: PERI-STEMI is an investigator-initiated, prospective, multi-center, randomized, open-label, superiority trial with blinded evaluation of outcomes. A total of 376 first-time STEMI patients with primary percutaneous coronary intervention (PPCI) within 12 h after symptom onset will be randomized to sacubitril-valsartan or enalapril treatment. All the patients will receive a baseline cardiovascular magnetic resonance (CMR) examination at 4-7 days post-PPCI. The primary endpoint is the change of indexed LV mass at the 6-month follow-up CMR.Results: Enrollment of the first patient is planned in November 2021. Recruitment is anticipated to last for 12-18 months and patients will be followed for 5 years after randomization. The study is expected to complete in June 2027.Jiayu Sun and Yong He co-supervise the work.

show abstract

Section: Discussionmentioning

confidence: 99%

Rationale and design of a multi‐center, prospective randomized controlled trial on the effects of sacubitril–valsartan versus enalapril on left ventricular remodeling in ST‐elevation myocardial infarction: The PERI‐STEMI study

Diao

Wang

Chen

et al. 2021

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…Myocardial injury promotes the inflammatory response, which manifests as activation of innate immune cells, tissue repair/remodeling, adaptive immune cell activation, and angiogenesis/fibrosis [72][73][74][75]. One of the first immune cell types to respond to injury is tissue-resident macrophages.…”

Section: Nanomedicine Boost Immunotherapy For Cardiovascular Inflamma...mentioning

confidence: 99%

Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment

Liu

Fan

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Acute myocardial infarction is a major global health problem, and the repair of damaged myocardium is still a major challenge. Myocardial injury triggers an inflammatory response: immune cells infiltrate into the myocardium while activating myofibroblasts and vascular endothelial cells, promoting tissue repair and scar formation. Fragments released by cardiomyocytes become endogenous “danger signals”, which are recognized by cardiac pattern recognition receptors, activate resident cardiac immune cells, release thrombin factors and inflammatory mediators, and trigger severe inflammatory responses. Inflammatory signaling plays an important role in the dilation and fibrosis remodeling of the infarcted heart, and is a key event driving the pathogenesis of post-infarct heart failure. At present, there is no effective way to reverse the inflammatory microenvironment in injured myocardium, so it is urgent to find new therapeutic and diagnostic strategies. Nanomedicine, the application of nanoparticles for the prevention, treatment, and imaging of disease, has produced a number of promising applications. This review discusses the treatment and challenges of myocardial injury and describes the advantages of functional nanoparticles in regulating the myocardial inflammatory microenvironment and overcoming side effects. In addition, the role of inflammatory signals in regulating the repair and remodeling of infarcted hearts is discussed, and specific therapeutic targets are identified to provide new therapeutic ideas for the treatment of myocardial injury.

show abstract

“…The similar epidemiological trends and the bidirectional feedback interactions between the heart and the brain are expected to cause a major increase in the prevalence of CI in HF ( 3 ). HF is generally considered a leading cause of hospitalization and mortality with an estimated prevalence of >64 million individuals worldwide ( 4 , 5 ). CI is a very frequent comorbidity in patients with HF and is increasingly recognized as the major cause of chronic disability.…”

Section: Introductionmentioning

confidence: 99%

Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions

Yang

Sun

Wang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Heart failure (HF) is a major global healthcare problem accounting for substantial deterioration of prognosis. As a complex clinical syndrome, HF often coexists with multi-comorbidities of which cognitive impairment (CI) is particularly important. CI is increasing in prevalence among patients with HF and is present in around 40%, even up to 60%, of elderly patients with HF. As a potent and independent prognostic factor, CI significantly increases the hospitalization and mortality and decreases quality of life in patients with HF. There has been a growing awareness of the complex bidirectional interaction between HF and CI as it shares a number of common pathophysiological pathways including reduced cerebral blood flow, inflammation, and neurohumoral activations. Research that focus on the precise mechanism for CI in HF is still ever insufficient. As the tremendous adverse consequences of CI in HF, effective early diagnosis of CI in HF and interventions for these patients may halt disease progression and improve prognosis. The current clinical guidelines in HF have begun to emphasize the importance of CI. However, nearly half of CI in HF is underdiagnosed, and few recommendations are available to guide clinicians about how to approach CI in patients with HF. This review aims to synthesize knowledge about the link between HF and cognitive dysfunction, issues pertaining to screening, diagnosis and management of CI in patients with HF, and emerging therapies for prevention. Based on data from current studies, critical gaps in knowledge of CI in HF are identified, and future research directions to guide the field forward are proposed.

show abstract

The year in cardiovascular medicine 2020: heart failure and cardiomyopathies

Abstract: Abstract

Cited by 29 publications

References 155 publications

Rationale and design of a multi‐center, prospective randomized controlled trial on the effects of sacubitril–valsartan versus enalapril on left ventricular remodeling in ST‐elevation myocardial infarction: The PERI‐STEMI study

Rationale and design of a multi‐center, prospective randomized controlled trial on the effects of sacubitril–valsartan versus enalapril on left ventricular remodeling in ST‐elevation myocardial infarction: The PERI‐STEMI study

Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment

Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions

Contact Info

Product

Resources

About